Cargando…
Carbapenems versus β-lactam and β-lactamase inhibitors for treatment of nosocomial pneumonia: A systematic review and meta-analysis
BACKGROUND: Carbapenems and β-lactam and β‐lactamase inhibitors (BLBLIs) have been used empirically in nosocomial pneumonia, but their efficacy and safety are controversial. OBJECTIVE: We carried out a systematic review with meta-analysis to evaluate the efficacy and safety of carbapenems versus BLB...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520732/ https://www.ncbi.nlm.nih.gov/pubmed/37767465 http://dx.doi.org/10.1016/j.heliyon.2023.e20108 |
_version_ | 1785109986368552960 |
---|---|
author | Cang, Huai Qin Quan, Xiang Hua Chu, Xiang Hua Liang, Yu Yang, Xue Li, Jing |
author_facet | Cang, Huai Qin Quan, Xiang Hua Chu, Xiang Hua Liang, Yu Yang, Xue Li, Jing |
author_sort | Cang, Huai Qin |
collection | PubMed |
description | BACKGROUND: Carbapenems and β-lactam and β‐lactamase inhibitors (BLBLIs) have been used empirically in nosocomial pneumonia, but their efficacy and safety are controversial. OBJECTIVE: We carried out a systematic review with meta-analysis to evaluate the efficacy and safety of carbapenems versus BLBLIs against nosocomial pneumonia. METHODS: PubMed, Embase, Cochrane Central Register of Controlled Trials, CNKI, Wangfang, VIP and Sinomed were searched systematically through April 29, 2023 for clinical trials comparing carbapenems with BLBLIs for treatment of nosocomial pneumonia. Random-effects models were used to evaluate the impact of treatment on the risk ratio (RR) of all-cause mortality, clinical response, microbiologic response, resistance by Pseudomonas aeruginosa, adverse effects (AEs), and serious adverse effects. The quality of the evidence was assessed with the Cochrane risk of bias tool. The review was registerted in the INPLASY (INPLASY202340113). RESULTS: Seven randomized controlled trials containing 3306 patients met our inclusion criteria Our meta-analysis showed no significant difference in all-cause mortality (RR = 0.88, 95% confidence interval [CI] = 0.75–1.03, I(2) = 0%) or clinical cure (1.02, 0.96–1.09, 30%) or clinical failure (1.19, 0.97–1.47, 0%) or microbiologic clinical cure (0.98, 0.89–1.06, 40%) or Pseudomonas aeruginosa resistance (RR 2.43, CI 0.86–6.81, 49%, P = 0.09) or adverse events (0.98, 0.93–1.02, 0%) between carbapenems groups versus BLBLIs groups, but a significant difference was found for severe adverse events (RR 0.83, CI 0.73−0.94, 0%). CONCLUSION: Differences in the prevalence of mortality, clinical cure, or clinical failure were not observed between carbapenems groups versus BLBLIs groups in terms of nosocomial pneumonia. The use of carbapenems was linked to a tendency towards the emergence of P. aeruginosa resistance, however, no statistically significant difference was observed. |
format | Online Article Text |
id | pubmed-10520732 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-105207322023-09-27 Carbapenems versus β-lactam and β-lactamase inhibitors for treatment of nosocomial pneumonia: A systematic review and meta-analysis Cang, Huai Qin Quan, Xiang Hua Chu, Xiang Hua Liang, Yu Yang, Xue Li, Jing Heliyon Research Article BACKGROUND: Carbapenems and β-lactam and β‐lactamase inhibitors (BLBLIs) have been used empirically in nosocomial pneumonia, but their efficacy and safety are controversial. OBJECTIVE: We carried out a systematic review with meta-analysis to evaluate the efficacy and safety of carbapenems versus BLBLIs against nosocomial pneumonia. METHODS: PubMed, Embase, Cochrane Central Register of Controlled Trials, CNKI, Wangfang, VIP and Sinomed were searched systematically through April 29, 2023 for clinical trials comparing carbapenems with BLBLIs for treatment of nosocomial pneumonia. Random-effects models were used to evaluate the impact of treatment on the risk ratio (RR) of all-cause mortality, clinical response, microbiologic response, resistance by Pseudomonas aeruginosa, adverse effects (AEs), and serious adverse effects. The quality of the evidence was assessed with the Cochrane risk of bias tool. The review was registerted in the INPLASY (INPLASY202340113). RESULTS: Seven randomized controlled trials containing 3306 patients met our inclusion criteria Our meta-analysis showed no significant difference in all-cause mortality (RR = 0.88, 95% confidence interval [CI] = 0.75–1.03, I(2) = 0%) or clinical cure (1.02, 0.96–1.09, 30%) or clinical failure (1.19, 0.97–1.47, 0%) or microbiologic clinical cure (0.98, 0.89–1.06, 40%) or Pseudomonas aeruginosa resistance (RR 2.43, CI 0.86–6.81, 49%, P = 0.09) or adverse events (0.98, 0.93–1.02, 0%) between carbapenems groups versus BLBLIs groups, but a significant difference was found for severe adverse events (RR 0.83, CI 0.73−0.94, 0%). CONCLUSION: Differences in the prevalence of mortality, clinical cure, or clinical failure were not observed between carbapenems groups versus BLBLIs groups in terms of nosocomial pneumonia. The use of carbapenems was linked to a tendency towards the emergence of P. aeruginosa resistance, however, no statistically significant difference was observed. Elsevier 2023-09-13 /pmc/articles/PMC10520732/ /pubmed/37767465 http://dx.doi.org/10.1016/j.heliyon.2023.e20108 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Article Cang, Huai Qin Quan, Xiang Hua Chu, Xiang Hua Liang, Yu Yang, Xue Li, Jing Carbapenems versus β-lactam and β-lactamase inhibitors for treatment of nosocomial pneumonia: A systematic review and meta-analysis |
title | Carbapenems versus β-lactam and β-lactamase inhibitors for treatment of nosocomial pneumonia: A systematic review and meta-analysis |
title_full | Carbapenems versus β-lactam and β-lactamase inhibitors for treatment of nosocomial pneumonia: A systematic review and meta-analysis |
title_fullStr | Carbapenems versus β-lactam and β-lactamase inhibitors for treatment of nosocomial pneumonia: A systematic review and meta-analysis |
title_full_unstemmed | Carbapenems versus β-lactam and β-lactamase inhibitors for treatment of nosocomial pneumonia: A systematic review and meta-analysis |
title_short | Carbapenems versus β-lactam and β-lactamase inhibitors for treatment of nosocomial pneumonia: A systematic review and meta-analysis |
title_sort | carbapenems versus β-lactam and β-lactamase inhibitors for treatment of nosocomial pneumonia: a systematic review and meta-analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520732/ https://www.ncbi.nlm.nih.gov/pubmed/37767465 http://dx.doi.org/10.1016/j.heliyon.2023.e20108 |
work_keys_str_mv | AT canghuaiqin carbapenemsversusblactamandblactamaseinhibitorsfortreatmentofnosocomialpneumoniaasystematicreviewandmetaanalysis AT quanxianghua carbapenemsversusblactamandblactamaseinhibitorsfortreatmentofnosocomialpneumoniaasystematicreviewandmetaanalysis AT chuxianghua carbapenemsversusblactamandblactamaseinhibitorsfortreatmentofnosocomialpneumoniaasystematicreviewandmetaanalysis AT liangyu carbapenemsversusblactamandblactamaseinhibitorsfortreatmentofnosocomialpneumoniaasystematicreviewandmetaanalysis AT yangxue carbapenemsversusblactamandblactamaseinhibitorsfortreatmentofnosocomialpneumoniaasystematicreviewandmetaanalysis AT lijing carbapenemsversusblactamandblactamaseinhibitorsfortreatmentofnosocomialpneumoniaasystematicreviewandmetaanalysis |